Dapagliflozin ((2S)-1,2-propanediol, hydrate) is the S-enantiomer of Dapagliflozin 1,2-propanediol, hydrate.
Dapagliflozin ((2S)-1,2-propanediol, hydrate), a new type of drug used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine.
Dapagliflozin ((2S)-1,2-propanediol, hydrate) induces HIF1 expression and attenuates renal IR injury.
体外研究
Dapagliflozin ((2S)-1,2-propanediol, hydrate) (0-10 μM; 24 hours) significantly increases the cell survival in hypoxic HK2 cell in a dose-dependent manner. Dapagliflozin ((2S)-1,2-propanediol, hydrate) (0-10 μM; 2 hours) increases the HIF1 expression, increases AMPK and EKR phosphorylation in hypoxic HK2 cells, but shows no effect on the phosphorylation of AMPK and ERK in normoxic HK2 cells.
Cell Viability Assay
Cell Line:
Hypoxic HK2 cell
Concentration:
0 μM, 1 μM, 2 μM, 5 μM, 10 μM
Incubation Time:
24 hours
Result:
Improved the cell viability in a dose-dependent manner compared with control cells.
Western Blot Analysis
Cell Line:
Hypoxic HK2 cell, Normoxic HK2 cells
Concentration:
0 μM, 1 μM, 2 μM, 5 μM, 10 μM
Incubation Time:
24 hours
Result:
Induced HIF1 expression in hypoxic and normoxic HK2 cells.